Carfilzomib-induced cardiovascular toxicity

20 Sep 2021

Prof. Dimitrios Farmakis from University of Cyprus Medical School, Nicosia, Cyprus and Dr. Alexander Lyon from the Royal Brompton Hospital and Imperial College, London, UK, discuss Carfilzomib-induced cardiovascular toxicity

 

Link to the publication cited in the discussion

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.